Comprehensive Stock Comparison
Compare ADMA Biologics, Inc. (ADMA) vs Agios Pharmaceuticals, Inc. (AGIO) Stock
Analyze side-by-side fundamentals, valuation, growth, and profitability to decide which stock is the better buy.
Selected Stocks
Add up to 10 tickers. Use presets or search to get started.
Quick Verdict
| Category | Winner | Why |
|---|---|---|
| Growth | ADMA | 65.2% revenue growth vs AGIO's 48.0% |
| Quality / Margins | ADMA | 42.9% net margin vs AGIO's -9.0% |
| Stability / Safety | AGIO | Beta 0.91 vs ADMA's 1.10, lower leverage |
| Dividends | Tie | Neither pays a meaningful dividend |
| Momentum (1Y) | ADMA | -5.0% vs AGIO's -14.9% |
| Efficiency (ROA) | ADMA | 36.8% ROA vs AGIO's -29.0%, ROIC 37.7% vs -26.6% |
Who Each Stock Is For
Income & stability
Growth exposure
Long-term compounding (10Y)
Sleep-well-at-night portfolio
Defensive / Recession hedge
Business Model
What each company does and how it makes money
ADMA Biologics is a biopharmaceutical company that develops, manufactures, and markets specialty plasma-derived biologics for treating immune deficiencies and infectious diseases. It generates revenue primarily from sales of its intravenous immune globulin products — BIVIGAM and ASCENIV — along with its Hepatitis B treatment Nabi-HB, while also operating plasma collection facilities. The company's key advantage is its integrated business model that combines plasma collection, manufacturing, and commercialization, creating a vertically controlled supply chain for plasma-derived therapies.
Agios Pharmaceuticals is a biopharmaceutical company focused on developing treatments for rare genetic diseases related to cellular metabolism. It generates revenue primarily from sales of its lead drug PYRUKYND for pyruvate kinase deficiency — with additional income from research collaborations and milestone payments — while advancing a pipeline of other metabolic therapies. The company's competitive advantage lies in its deep expertise in cellular metabolism science and proprietary platform for targeting metabolic pathways in rare diseases.
Revenue Breakdown by Segment
How each company's revenue is distributed across its business units
Financial Metrics Comparison
Side-by-side fundamentals across 2 stocks. BestLagging
Financial Scorecard
ADMA leads in 3 of 6 categories (Financial Metrics, Profitability & Efficiency). AGIO leads in 2 (Valuation Metrics, Risk & Volatility).
Financial Metrics (TTM)
ADMA is the larger business by revenue, generating $489M annually — 10.9x AGIO's $45M. ADMA is the more profitable business, keeping 42.9% of every revenue dollar as net income compared to AGIO's -9.0%. On growth, AGIO holds the edge at +43.7% YoY revenue growth, suggesting stronger near-term business momentum.
| Metric | ADMAADMA Biologics, I… | AGIOAgios Pharmaceuti… |
|---|---|---|
| RevenueTrailing 12 months | $489M | $45M |
| EBITDAEarnings before interest/tax | $175M | -$470M |
| Net IncomeAfter-tax profit | $209M | -$401M |
| Free Cash FlowCash after capex | $41M | -$414M |
| Gross MarginGross profit ÷ Revenue | +54.7% | +84.4% |
| Operating MarginEBIT ÷ Revenue | +34.2% | -10.6% |
| Net MarginNet income ÷ Revenue | +42.9% | -9.0% |
| FCF MarginFCF ÷ Revenue | +8.3% | -9.2% |
| Rev. Growth (YoY)Latest quarter vs prior year | +12.0% | +43.7% |
| EPS Growth (YoY)Latest quarter vs prior year | 0.0% | -111.0% |
Valuation Metrics
| Metric | ADMAADMA Biologics, I… | AGIOAgios Pharmaceuti… |
|---|---|---|
| Market CapShares × price | $3.7B | $2.25T |
| Enterprise ValueMkt cap + debt − cash | $3.7B | $2.25T |
| Trailing P/EPrice ÷ TTM EPS | 19.22x | -4.25x |
| Forward P/EPrice ÷ next-FY EPS est. | 16.30x | — |
| PEG RatioP/E ÷ EPS growth rate | — | — |
| EV / EBITDAEnterprise value multiple | 25.10x | — |
| Price / SalesMarket cap ÷ Revenue | 8.70x | 9999.00x |
| Price / BookPrice ÷ Book value/share | 10.86x | 1.47x |
| Price / FCFMarket cap ÷ FCF | 33.71x | — |
Profitability & Efficiency
ADMA delivers a 48.6% return on equity — every $100 of shareholder capital generates $49 in annual profit, vs $-31 for AGIO. AGIO carries lower financial leverage with a 0.03x debt-to-equity ratio, signaling a more conservative balance sheet compared to ADMA's 0.24x. On the Piotroski fundamental quality scale (0–9), ADMA scores 7/9 vs AGIO's 3/9, reflecting strong financial health.
| Metric | ADMAADMA Biologics, I… | AGIOAgios Pharmaceuti… |
|---|---|---|
| ROE (TTM)Return on equity | +48.6% | -31.2% |
| ROA (TTM)Return on assets | +36.8% | -29.0% |
| ROICReturn on invested capital | +37.7% | -26.6% |
| ROCEReturn on capital employed | +39.0% | -33.8% |
| Piotroski ScoreFundamental quality 0–9 | 7 | 3 |
| Debt / EquityFinancial leverage | 0.24x | 0.03x |
| Net DebtTotal debt minus cash | -$21M | -$49M |
| Cash & Equiv.Liquid assets | $103M | $89M |
| Total DebtShort + long-term debt | $82M | $40M |
| Interest CoverageEBIT ÷ Interest expense | 19.63x | — |
Total Returns (with DRIP)
A $10,000 investment in ADMA five years ago would be worth $64,339 today (with dividends reinvested), compared to $6,363 for AGIO. Over the past 12 months, ADMA leads with a -5.0% total return vs AGIO's -14.9%. The 3-year compound annual growth rate (CAGR) favors ADMA at 63.7% vs AGIO's 6.1% — a key indicator of consistent wealth creation.
| Metric | ADMAADMA Biologics, I… | AGIOAgios Pharmaceuti… |
|---|---|---|
| YTD ReturnYear-to-date | -12.9% | +11.2% |
| 1-Year ReturnPast 12 months | -5.0% | -14.9% |
| 3-Year ReturnCumulative with dividends | +338.6% | +19.4% |
| 5-Year ReturnCumulative with dividends | +543.4% | -36.4% |
| 10-Year ReturnCumulative with dividends | +227.8% | -21.2% |
| CAGR (3Y)Annualised 3-year return | +63.7% | +6.1% |
Risk & Volatility
AGIO is the less volatile stock with a 0.91 beta — it tends to amplify market swings less than ADMA's 1.10 beta. A beta below 1.0 means the stock typically moves less than the S&P 500. AGIO currently trades 65.7% from its 52-week high vs ADMA's 60.7% drawdown — a narrower gap to the peak suggests stronger recent price momentum.
| Metric | ADMAADMA Biologics, I… | AGIOAgios Pharmaceuti… |
|---|---|---|
| Beta (5Y)Sensitivity to S&P 500 | 1.10x | 0.91x |
| 52-Week HighHighest price in past year | $25.67 | $46.00 |
| 52-Week LowLowest price in past year | $13.50 | $22.24 |
| % of 52W HighCurrent price vs 52-week peak | +60.7% | +65.7% |
| RSI (14)Momentum oscillator 0–100 | 35.7 | 62.3 |
| Avg Volume (50D)Average daily shares traded | 1.8M | 948K |
Analyst Outlook
Wall Street rates ADMA as "Buy" and AGIO as "Buy". Consensus price targets imply 37.3% upside for AGIO (target: $42) vs 2.8% for ADMA (target: $16).
| Metric | ADMAADMA Biologics, I… | AGIOAgios Pharmaceuti… |
|---|---|---|
| Analyst RatingConsensus buy/hold/sell | Buy | Buy |
| Price TargetConsensus 12-month target | $16.00 | $41.50 |
| # AnalystsCovering analysts | 9 | 29 |
| Dividend YieldAnnual dividend ÷ price | — | — |
| Dividend StreakConsecutive years of raises | 1 | — |
| Dividend / ShareAnnual DPS | — | — |
| Buyback YieldShare repurchases ÷ mkt cap | 0.0% | 0.0% |
Historical Charts
Charts are rendered on first load. Hover for details.
Chart 1Total Return — 5 Years (Rebased to 100)
| Stock | Mar 20 | Feb 26 | Change |
|---|---|---|---|
| ADMA Biologics, Inc. (ADMA) | 100 | 589.23 | +489.2% |
| Agios Pharmaceutica… (AGIO) | 100 | 57.07 | -42.9% |
ADMA Biologics, Inc. (ADMA) returned +543% over 5 years vs Agios Pharmaceutica… (AGIO)'s -36%. A $10,000 investment in ADMA 5 years ago would be worth $64,339 today (including dividends reinvested).
Chart 2Revenue Growth — 10 Years
| Stock | 2016 | 2025 | Change |
|---|---|---|---|
| ADMA Biologics, Inc. (ADMA) | $11M | $426M | +3900.1% |
| Agios Pharmaceutica… (AGIO) | $70M | $54M | -22.7% |
Agios Pharmaceuticals, Inc.'s revenue grew from $70M (2016) to $54M (2025) — a -2.8% CAGR.
Chart 3Net Margin Trend — 10 Years
| Stock | 2016 | 2025 | Change |
|---|---|---|---|
| ADMA Biologics, Inc. (ADMA) | -183.1% | 46.4% | +125.3% |
| Agios Pharmaceutica… (AGIO) | -2.8% | -7.6% | -169.0% |
Agios Pharmaceuticals, Inc.'s net margin went from -3% (2016) to -8% (2025).
Chart 4EPS Growth — 10 Years
| Stock | 2016 | 2025 | Change |
|---|---|---|---|
| ADMA Biologics, Inc. (ADMA) | -1.61 | 0.81 | +150.3% |
| Agios Pharmaceutica… (AGIO) | -5.07 | -7.12 | -40.4% |
Agios Pharmaceuticals, Inc.'s EPS grew from $-5.07 (2016) to $-7.12 (2025).
Chart 5Free Cash Flow — 5 Years
ADMA Biologics, Inc. generated $110M FCF in 2024 (+187% vs 2021). Agios Pharmaceuticals, Inc. generated $-377M FCF in 2025 (+9% vs 2021).
ADMA vs AGIO: Frequently Asked Questions
8 questions · data-driven answers · updated daily
01Is ADMA or AGIO a better buy right now?
ADMA Biologics, Inc. (ADMA) offers the better valuation at 19.2x trailing P/E (16.3x forward), making it the more compelling value choice. Analysts rate ADMA Biologics, Inc. (ADMA) a "Buy" — based on 9 analyst ratings — the highest consensus in this comparison. The "better buy" depends entirely on your goals: growth investors should weight revenue trajectory, value investors should weight P/E and PEG, and income investors should weight dividend yield and streak.
02Which is the better long-term investment — ADMA or AGIO?
Over the past 5 years, ADMA Biologics, Inc. (ADMA) delivered a total return of +543.4%, compared to -36.4% for Agios Pharmaceuticals, Inc. (AGIO). A $10,000 investment in ADMA five years ago would be worth approximately $64K today (assuming dividends reinvested). Over 10 years, the gap is even starker: ADMA returned +227.8% versus AGIO's -21.2%. Past returns do not guarantee future results, and the stock with the higher historical return may already have its best growth priced in.
03Which is safer — ADMA or AGIO?
By beta (market sensitivity over 5 years), Agios Pharmaceuticals, Inc. (AGIO) is the lower-risk stock at 0.91β versus ADMA Biologics, Inc.'s 1.10β — meaning ADMA is approximately 22% more volatile than AGIO relative to the S&P 500. On balance sheet safety, Agios Pharmaceuticals, Inc. (AGIO) carries a lower debt/equity ratio of 3% versus 24% for ADMA Biologics, Inc. — giving it more financial flexibility in a downturn.
04Which has better profit margins — ADMA or AGIO?
ADMA Biologics, Inc. (ADMA) is the more profitable company, earning 46.4% net margin versus -764.0% for Agios Pharmaceuticals, Inc. — meaning it keeps 46.4% of every revenue dollar as bottom-line profit. Operating margin tells a similar story: ADMA leads at 32.6% versus -873.9% for AGIO. At the gross margin level — before operating expenses — AGIO leads at 88.3%, reflecting greater pricing power or product mix advantage. Stronger margins indicate durable pricing power, lower cost of revenue, or higher mix of software/services. They are one of the clearest signs of business quality.
05Is ADMA or AGIO more undervalued right now?
Analyst consensus price targets imply the most upside for AGIO: 37.3% to $41.50.
06Which pays a better dividend — ADMA or AGIO?
None of the stocks in this comparison currently pay a material dividend. All are effectively zero-yield and should be held for capital appreciation rather than income.
07Is ADMA or AGIO better for a retirement portfolio?
For long-horizon retirement investors, Agios Pharmaceuticals, Inc. (AGIO) is the stronger choice — it scores higher on the combination of lower volatility, dividend reliability, and long-term compounding (low volatility (β 0.91)). Both have compounded well over 10 years (AGIO: -21.2%, ADMA: +227.8%), confirming both are viable long-term holds — but the lower-volatility option typically results in less emotional selling during corrections. Retirement portfolios generally favour predictability over maximum returns. Consult a financial advisor before making allocation decisions.
08What are the main differences between ADMA and AGIO?
Both stocks operate in the Healthcare sector, making this a peer-level intra-sector comparison — the same macro tailwinds and headwinds will affect both. These fundamental differences mean investors should not choose between them on a single metric — the "better stock" depends entirely on which of these characteristics aligns with your investment strategy.
Find Stocks Like These
Explore pre-built screens for each stock's profile, or build a custom screen to find stocks that beat both.